Phunware ab 27.02.24 RS WKN: A404G9 ISIN: US71948P2092 Kürzel: PHUN Forum: Aktien User: Lusaja12
On November 1, 2024, Phunware, Inc. (the "Company*) entered into an Amended and Restated Equity Distribution Agreement (the "A&R Distribution Agreement*) with Canaccord Genuity LLC ("Canaccord"), as representative of the several agents named on Schedule 1 thereto (collectively, and together with Canaccord, the "Agents"), which amends and restates that certain Equity Distribution Agreement by and between the Company and Canaccord dated June 4, 2024 (the "Original Distribution Agreement*). Pursuant to the A&R Distribution Agreement, the Company may offer and sell, from time to time, shares of the Company's common stock, par value $0.0001 per share, through the Agents, as sales agents for the shares, for aggregate gross proceeds of up to $171,520,779 (the "Shares"), inclusive of all Shares sold under the Original Distribution Agreement (the "Offering").
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | Germany 40 Hauptdiskussion | -0,09 % | |
| 2 | MICRON TECHNOLOGY Hauptdiskussion | -3,97 % | |
| 3 | OTL nach dem RS 1:20 | -1,69 % | |
| 4 | BMW Hauptdiskussion | -0,21 % | |
| 5 | Germany 40 / DAX Prognose | -0,09 % | |
| 6 | BioXcel Therapeutics Inc Registered Shs Hauptdiskussion | -0,41 % | |
| 7 | Super Micro Computer Hauptdiskussion | -1,66 % | |
| 8 | Ondas Holdings | -0,75 % | |
| 9 | NEL ASA Hauptdiskussion | ±0,00 % | |
| 10 | TUI Hauptforum | +0,91 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | MICRON TECHNOLOGY Hauptdiskussion | -3,72 % | |
| 2 | OTL nach dem RS 1:20 | -1,69 % | |
| 3 | BMW Hauptdiskussion | ±0,00 % | |
| 4 | BioXcel Therapeutics Inc Registered Shs Hauptdiskussion | -0,41 % | |
| 5 | SIVERS IMA HLDG Hauptdiskussion | -17,42 % | |
| 6 | NEL ASA Hauptdiskussion | ±0,00 % | |
| 7 | Ondas Holdings | -0,75 % | |
| 8 | Super Micro Computer Hauptdiskussion | -0,54 % | |
| 9 | TUI Hauptforum | +0,91 % | |
| 10 | BRAINCHIP HOLDINGS LTD Hauptdiskussion | -2,36 % | Alle Diskussionen |